PL2415763T3 - Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry - Google Patents

Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry

Info

Publication number
PL2415763T3
PL2415763T3 PL10758728T PL10758728T PL2415763T3 PL 2415763 T3 PL2415763 T3 PL 2415763T3 PL 10758728 T PL10758728 T PL 10758728T PL 10758728 T PL10758728 T PL 10758728T PL 2415763 T3 PL2415763 T3 PL 2415763T3
Authority
PL
Poland
Prior art keywords
treating
pharmaceutical composition
preventing glaucoma
glaucoma
preventing
Prior art date
Application number
PL10758728T
Other languages
English (en)
Inventor
Masahiko Hagihara
Kenji Yoneda
Eiji Okanari
Manabu Shigetomi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of PL2415763T3 publication Critical patent/PL2415763T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10758728T 2009-03-30 2010-03-30 Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry PL2415763T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009082725 2009-03-30
EP10758728.9A EP2415763B1 (en) 2009-03-30 2010-03-30 Pharmaceutical composition for treating or preventing glaucoma
PCT/JP2010/055719 WO2010113957A1 (ja) 2009-03-30 2010-03-30 緑内障の治療又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
PL2415763T3 true PL2415763T3 (pl) 2016-05-31

Family

ID=42828246

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10758728T PL2415763T3 (pl) 2009-03-30 2010-03-30 Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry

Country Status (17)

Country Link
US (1) US8685986B2 (pl)
EP (1) EP2415763B1 (pl)
JP (2) JP5300033B2 (pl)
KR (1) KR101681347B1 (pl)
CN (1) CN102448940B (pl)
AU (1) AU2010231630B2 (pl)
CA (1) CA2757291C (pl)
CY (1) CY1117193T1 (pl)
DK (1) DK2415763T3 (pl)
ES (1) ES2564010T3 (pl)
HR (1) HRP20160104T1 (pl)
HU (1) HUE026742T2 (pl)
PL (1) PL2415763T3 (pl)
PT (1) PT2415763E (pl)
SI (1) SI2415763T1 (pl)
SM (1) SMT201600055B (pl)
WO (1) WO2010113957A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
CN102666490A (zh) 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
HK1219103A1 (en) 2013-03-28 2017-03-24 Ube Industries, Ltd. Substituted biaryl compound
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3093018B1 (en) 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
US10519112B2 (en) 2014-06-10 2019-12-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
KR20170013994A (ko) * 2014-06-10 2017-02-07 우베 고산 가부시키가이샤 N-치환 술폰아미드 화합물 및 그의 제조 방법
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
CN107708738B (zh) * 2015-07-01 2022-03-25 参天制药株式会社 含有柠檬酸酯的贮库制剂
US20180200239A1 (en) * 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
WO2019065838A1 (ja) 2017-09-29 2019-04-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination
CN111526876A (zh) * 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
KR20220089106A (ko) 2020-12-21 2022-06-28 이성규 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물
CN118084895B (zh) * 2024-02-28 2025-09-05 中国药科大学 一种一氧化氮供体型Omidenepag衍生物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
JP2005507413A (ja) 2001-10-26 2005-03-17 アラーガン　インコーポレイテッド ＥＰ２−受容体作用薬としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似物
PY0300568A (es) 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US20070000939A1 (en) 2002-10-29 2007-01-04 Vasilios Vasiadis Device for handling and orientating pills or tablets in a precise manner
CA2518193A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
BRPI0606644A2 (pt) 2005-01-14 2009-07-14 Hoffmann La Roche derivados de 4-carboxamida tiazola
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
EP1912957A4 (en) 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
FI123744B (fi) * 2006-09-06 2013-10-15 Sandvik Mining & Constr Oy Menetelmä kallion poraamiseksi
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma

Also Published As

Publication number Publication date
CA2757291C (en) 2017-05-23
PT2415763E (pt) 2016-03-30
US20120190852A1 (en) 2012-07-26
CA2757291A1 (en) 2010-10-07
SMT201600055B (it) 2016-04-29
CN102448940A (zh) 2012-05-09
KR101681347B1 (ko) 2016-11-30
SI2415763T1 (sl) 2016-05-31
WO2010113957A1 (ja) 2010-10-07
HRP20160104T1 (hr) 2016-03-25
JP5300033B2 (ja) 2013-09-25
EP2415763A1 (en) 2012-02-08
HK1170490A1 (zh) 2013-03-01
CY1117193T1 (el) 2017-04-05
HUE026742T2 (en) 2016-07-28
US8685986B2 (en) 2014-04-01
ES2564010T3 (es) 2016-03-17
KR20120003475A (ko) 2012-01-10
JP2013151548A (ja) 2013-08-08
DK2415763T3 (en) 2016-03-07
AU2010231630B2 (en) 2015-02-12
JPWO2010113957A1 (ja) 2012-10-11
EP2415763B1 (en) 2016-01-27
EP2415763A4 (en) 2012-08-15
JP5556924B2 (ja) 2014-07-23
CN102448940B (zh) 2015-10-21
AU2010231630A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
SI2415763T1 (sl) Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma
SG175037A1 (en) Pharmaceutical composition
SI2470191T1 (sl) Postopki in sestavki za prepreäśevanje ali zdravljenje oftalmoloĺ kih stanj
ZA201108697B (en) Quinoline derivatives-containing pharmaceutical composition
ZA201505556B (en) Compositions for treating gaucher disease
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
IL214036A0 (en) Pharmaceutical composition for inhalation
IL209216A (en) Preparations for the prevention and treatment of neurodegenerative diseases
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
HU0900072D0 (en) Transdermal pharmaceutical compositions
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
EP2255825A4 (en) COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
IL209947A (en) Compounds for the treatment of corneal inflammation
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
PL2263454T3 (pl) Kompozycja uzdatniająca
EP2382992A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES
GB2486713B (en) Pharmaceutical composition for treating urinary system disorders
ZA201209537B (en) Pharmaceutical composition for treating drug addiction
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0919650D0 (en) Pharmaceutical composition
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
EP2785343A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA
PT2566506T (pt) Composição de vacina para a prevenção ou tratamento de leishmanioses